Studies related to Plasmalogens and Inositol

Myo-inositol Treatment Increases Serum Plasmalogens And Decreases Small Dense LDL, Particularly In Hyperlipidemic Subjects With Metabolic Syndrome

Effect None
Trial Design Non-controlled trial
Trial Length 1-2 Weeks
Number of Subjects 17
Sex Both Genders
Age Range 30-44, 45-64
Body Types Overweight
Notes for this study:
Two weeks supplementation of _myo_-inositol at 5g (first week) and 10g (second week) was able to increase circulating levels of choline plasmalogen, which is thought to be the reason behind a reduction in LDL-C. These changes were not present in persons without metabolic syndrome.

Full details on all 2 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.